PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older

Completed

Interventions: Diagnostic Test: Urine sample collection
Diagnostic Test: Saliva collection

Brief Summary: Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.

Detailed Description: PCV13 efficacy for the prevention of vaccine-type community-acquired pneumonia (VT-CAP) and invasive pneumococcal disease (IPD) was established in the Community-acquired Pneumonia Immunization Trial in Adults (CAPITA) aged 65 and older. However, there are still few available real-life effectiveness estimates in adults. The aim of this study is to evaluate the PCV13 vaccine effectiveness (VE) against hospitalised VT-pneumococcal CAP among adults aged ≥60 years in the Region of Madrid (Spain). Determination of the effectiveness of PCV13 to prevent hospitalised vaccine-type (VT)-pneumococcal CAP among adults aged ≥60 years in Madrid will be evaluated using a test-negative design study, overall and among immunocompetent persons only.

Recruitment & Eligibility

Inclusion Criteria

Age ≥60 years.
Evidence of pneumonia within first 48 hours of hospital admission
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria

Any patient who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these).
Previously enrolled subjects readmitted ≤14 days after discharge for their study qualifying admission.
At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.

Arm && Interventions

Group	Intervention	Description
All participants	Urine sample collection	-
All participants	Saliva collection	-

Primary Outcome Measures

Name	Time	Method
Vaccine effectiveness (VE)	4 years	VE calculated as 1 minus the OR\* comparing the odds of having received PCV13 for cases and controls, multiplied by 100, overall and restricted to immunocompetent subjects only.

Secondary Outcome Measures

Name	Time	Method
Proportion of participants with CAP and SP-CAP with underlying medical conditions	4 years	Proportion of CAP subjects with underlying at-risk and high-risk medical conditions, overall and restricted to those with pneumococcus isolated from blood, high-quality respiratory cultures, and a serotype specific urinary antigen detection (UAD) assay
Frequency of antibiotic resistance among Streptococcus pneumoniae isolates by type	4 years	Proportion of S. pneumoniae isolates with antibiotic resistance identified by standard of care testing, overall and by resistance type
Proportion of CAP events for each pneumococcal serotype, PCV-13, and 20-valent pneumococcal conjugate vaccine (PCV20) serotypes among all CAP subjects with UAD1/2 testing (overall) and among all CAP subjects with a pneumococcus identified	4 years	Distribution of S. pneumoniae serotypes using blood, high-quality respiratory cultures, and a serotype-specific urinary antigen detection (UAD) assay among adults 60 years of age and older with CAP.
Proportion of persons with respiratory pneumococcal carriage among adults 60 years of age and older presenting with CAP	4 years	Proportion of CAP events where the pneumococcus was identified from saliva by the conventional culture or the sensitive molecular method of PCR divided by all CAP events where the subject had a valid saliva specimen test result.

Locations (6): Hospital Universitario de Mostoles
🇪🇸
Mostoles, Madrid, Spain
Hospital Universitarios De Getafe
🇪🇸
Getafe, Madrid, Spain
Hospital Universitario Severo Ochoa
🇪🇸
Leganés, Madrid, Spain
Hospital Universitario Rey Juan carlos
🇪🇸
Móstoles, Spain
Hospital Universitario Fundación Alcorcón
🇪🇸
Alcorcón, Madrid, Spain
Hospital Universitario de Móstoles / Servicio de Oncología Médica
🇪🇸
Mostoles, Spain